ADXN.SW Addex Therapeutics (SIX) up 5.91% pre-market 18 Mar 2026: watch catalysts and liquidity

Pre-market trading flags ADXN.SW stock after a 5.91% uptick to CHF 0.0466 on 18 Mar 2026. Addex Therapeutics Ltd (ADXN.SW) on the SIX market hit a day high of CHF 0.0466 with volume at 16,384 shares. We look at what moved the price, how valuation and technicals line up, and what traders should watch ahead of the company’s next earnings and pipeline catalysts. This Meyka AI-powered market analysis platform note frames short-term trade setups and the longer term forecast.

Pre-market price action: ADXN.SW stock key stats

ADXN.SW stock trades on the SIX exchange in Switzerland at CHF 0.0466, up 5.91% from the previous close of CHF 0.0440. The session high is CHF 0.0466 and the low is CHF 0.0432. Volume is 16,384 versus an average volume of 166,126, and market cap is CHF 7,030,630.

Shares outstanding total 150,871,899. Reported EPS is -0.06 with a PE shown at -0.78. The 50-day average price is CHF 0.0503 and the 200-day average is CHF 0.0570, so price sits below both moving averages.

Why ADXN.SW stock appears on high-volume movers radar

The stock is in our high-volume movers watchlist because the price jump came ahead of the company’s scheduled earnings announcement on 27 Apr 2026. Addex’s pipeline, notably Dipraglurant and GABAB PAM programs, keeps the name volatile in biotech trading windows.

Sector context matters. Healthcare sector momentum is muted, with 3-month performance near -3.03%, which raises the odds that company-specific news or trial updates drive trades in ADXN.SW rather than broad sector flows. Traders should watch for press releases and clinical updates.

Meyka AI rates ADXN.SW with a score out of 100 and valuation view

Meyka AI rates ADXN.SW with a score out of 100. The platform gives ADXN.SW a score of 66.83 (Grade B) and a suggestion of HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Valuation snapshots show price-to-book at 0.88, price-to-sales at 50.70, and cash per share at CHF 0.0195. The high price-to-sales ratio reflects development-stage revenues and limited sales. These metrics support a cautious view for investors focused on fundamentals.

Financials, fundamentals and forecast data for ADXN.SW stock

Addex is a development-stage biotech with limited revenue and persistent net losses. Revenue per share is 0.00 1 (TTM) and net income per share is -0.0541. Current ratio stands at 2.01, and debt is negligible versus market cap.

Meyka AI’s forecast model projects a quarterly target of CHF 0.05, a monthly target of CHF 0.03, a 12-month projection of CHF 0.031642, and a 3-year projection of CHF 0.011825. Compared with the current price of CHF 0.0466, the quarterly target implies an upside of 7.30%, while the 12-month projection implies a downside of 32.09%. Forecasts are model-based projections and not guarantees.

Technicals, trading levels and risk controls for ADXN.SW stock

Technical indicators show low momentum and oversold signals. RSI is 37.31, ADX is 12.84 indicating no clear trend, and CCI is -145.59. The immediate support is near the year low at CHF 0.0432, with resistance at the year high CHF 0.085 and the 50-day average CHF 0.0503.

Given tiny market cap and low liquidity, position sizing matters. Use tight risk controls. For short-term trades, consider stops below CHF 0.0430 and scale out near resistance. For longer holds, watch clinical readouts and the 27 Apr 2026 earnings window.

Trading outlook and catalyst calendar for ADXN.SW stock

Key catalysts include the earnings announcement on 27 Apr 2026 and any trial or licensing updates from Dipraglurant and ADX71149 programs. Collaborations with Janssen and Indivior remain headline drivers for partnership or milestone news.

Liquidity is constrained, so expect wide intraday swings. The stock is suited to active traders and speculative biotech accounts. For deeper background see the company site and our Meyka stock page source Meyka ADXN.SW page.

Final Thoughts

ADXN.SW stock trades at CHF 0.0466 after a 5.91% pre-market rise on 18 Mar 2026. Short-term momentum is weak but clinical or earnings news can trigger sharp moves. Meyka AI’s forecast model offers a near-term quarterly target of CHF 0.05 (implied upside 7.30%) and a 12-month projection of CHF 0.031642 (implied downside 32.09%). Meyka AI assigns ADXN.SW a B grade (66.83) and a HOLD suggestion based on benchmark and sector comparisons, growth metrics, and analyst inputs. Trading ADXN.SW requires tight stops, small position sizes, and event-driven monitoring because of low market cap CHF 7,030,630 and limited liquidity. Forecasts are model-based projections and not guarantees. Watch the earnings date on 27 Apr 2026 and any trial updates for actionable news that could change both technicals and valuation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.